Made available in DSpace on 2014-12-17T14:16:28Z (GMT). No. of bitstreams: 1
RobertoCV_DISSERT.pdf: 2201581 bytes, checksum: a5ed04f6ae5794f328192fe513bdf03f (MD5)
Previous issue date: 2010-02-24 / Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior / The acute myeloid leukemia (AML) is a disease in which malignant myeloblasts
expand, build up and suppress normal hematopoietic activity would represent a
major diagnostic challenge. With the advent of immunophenotyping by flow
cytometry, the diagnosis of these tumors have become more faithful, facilitating the
treatment and monitoring of patients. The objectives of this study: diagnosis and
classification of AML based on immunophenotyping by flow cytometry with a panel of
AcMo specific for acute leukemias, set the frequency of AML in samples from
patients with acute leukemias sent to the Department of Hematology Blood Center of
Rio Grande do Norte - HEMONORTE, establish standards of antigen expression for
different subtypes of acute leukemia and its correlation with the newly diagnosed
cases refractory to treatment and recurrence of the disease, standardization of
methods for detection and labeling of surface antigens by flow cytometry and
intracytoplasmic flow, and observe the frequency of acute leukemia with aberrant
phenotypes rare. During the study, 351 were diagnosed acute leukemia, and 179
(51%) classified as AML and 172 (49%) and ALL, which were excluded from the
present work. Of the 179 AML, 92 (51.4%) were female and 87 (48.6%) were male,
with ages ranging from 3 to 95 years of ag, with higher incidence in individuals in the
age group of 41 to 65. Splenomegaly was the clinical finding more present, a total of
147 cases (82.1%), followed by hepatomegaly present in 132 cases (73.7%). The
hemorrhagic events were observed in 55 cases (30.7%). Lymphadenopathy in turn
was detected in 20 of 179 cases (11.2%). In order to classify subtypes of AML, we
used a large panel of monoclonal antibodies, obtaining the following results: AML
M0, 02 (1.1%) AML M1, 40 (22.3) AML M2, 60 (33.5) AML M3, 22 (12.3%) AML M4,
10 (5.6) AML M5, 13 (7.3%) AML M6 06 (3.4%) and AML M7 01 (0.6%). We
observed some cases with aberrant expression of some antigens such as CD7, CD4,
CD19, CD3, CD5 and TdT, CD 7 was present in 30 (16.8%), CD4 in 5 (2.8%), the CD
3 in 5 (2.8%), the CD19 in 3 (1.7%), the CD5 in 3 (1.7%) and TDT was in 7 (3.9%)
cases of AML .the CD8 and CD79a was present in only a 1 case. / A Leucemia Miel?ide Aguda (LMA) ? uma doen?a maligna em que os mieloblastos
expandem-se, acumulam-se e suprimem a atividade hematopo?tica normal,
constituindo um grande desafio diagn?stico. Com o advento da imunofenotipagem
por citometria de fluxo, o diagn?stico dessas neoplasias se tornaram mais fi?is,
facilitando o tratamento e o acompanhamento dos pacientes. Foram objetivos deste
estudo: diagnosticar e classificar as LMA com base na imunofenotipagem por
citometria de fluxo, com um painel de AcMo espec?fico para leucemias agudas;
estabelecer a frequ?ncia de LMA nas amostras de pacientes com leucemias agudas
encaminhadas ao Departamento de Hematologia do Hemocentro do Rio Grande do
Norte HEMONORTE; estabelecer padr?es de express?o antig?nica para os
diversos subtipos de leucemias agudas e a sua correla??o com os casos rec?m
diagnosticados, refrat?rios ao tratamento e recorr?ncia da doen?a; padroniza??o dos
m?todos de detec??o e marca??o de ant?genos de superf?cie e intracitoplasm?tico
por citometria de fluxo; e observar a freq??ncia de leucemias agudas com fen?tipos
aberrantes raros. Durante o estudo, foram diagnosticados 351 leucemias agudas,
sendo 179 (51%) classificadas como LMA e 172 (49%) como LLA, as quais foram
exclu?das do presente trabalho. Das 179 LMA, 92 (51,4%) eram do sexo feminino e
87 (48,6%) do sexo masculino, com faixa et?ria variando de 3 a 95 anos de idade,
com maior incid?ncia em indiv?duos na faixa et?ria de 41 a 65 anos. A
esplenomegalia foi o achado cl?nico mais presente, perfazendo um total de 147
casos (82,1%), seguida da hepatomegalia presente em 132 casos (73,7%). Os
fen?menos hemorragicos foram observado em 55 casos ( 30,7%). A linfoadenopatia
por sua vez foi constatada em 20 dos 179 casos (11,2%). Para classifica??o dos
subtipos de LMA foi utilizado um painel amplo de anticorpos monoclonais, obtendo
os seguintes resultados: LMA M0, 02 (1.1%) LMA M1, 40 (22.3) LMA M2, 60 (33.5)
LMA M3, 22 (12.3%) LMA M4, 10 (5.6) LMA M5, 13 (7.3%) LMA M6 06 (3.4%) e
LMA M7 01 (0.6%). Foram observados alguns casos com express?o aberrante de
alguns ant?genos tais como CD7, CD4, CD19, CD3, CD5 e TdT, O CD7 esteve
presente em 30 (16,8%) , o CD4 em 5 (2,8%), o CD 3 em 5 (2,8%), o CD19 em 3
(1,7%), o CD5 em 3 (1,7%) e o TDT esteve em 7 (3,9%) casos de LMA
diagnosticados.O CD8 e o CD79a esteve presente em apenas um 1 caso.
| Identifer | oai:union.ndltd.org:IBICT/oai:repositorio.ufrn.br:123456789/13464 |
| Date | 24 February 2010 |
| Creators | Vasconcelos, Roberto Chaves de |
| Contributors | CPF:10861203453, http://lattes.cnpq.br/0091662650633339, Freire, Fl?vio Henrique Miranda de Ara?jo, CPF:80698891449, http://lattes.cnpq.br/7623751650258443, Alves, Carlos Roberto, CPF:69898448768, Cavalcanti J?nior, Geraldo Barroso |
| Publisher | Universidade Federal do Rio Grande do Norte, Programa de P?s-Gradua??o em Ci?ncias Farmac?uticas, UFRN, BR, Bioan?lises e Medicamentos |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
| Format | application/pdf |
| Source | reponame:Repositório Institucional da UFRN, instname:Universidade Federal do Rio Grande do Norte, instacron:UFRN |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0022 seconds